Episode 7: CEO Insights: Immunotherapy Innovations, AI Challenges and Clinical Trial Observations

In our new episode CEO Insights: Immunotherapy Innovations, AI Challenges and Clinical Trial Observations, our CEO & Founder, Alan Vanderborght, sits down with David Apelian, CEO at Theolytics.

Together, they explore various current industry topics, focusing on exciting immunotherapy innovations, AI pros and cons and clinical trial observations.

Listen Below:

CEO Insights: Immunotherapy Innovations, AI Challenges and Clinical Trial Observations
TAGS:

About the author.

administrator

20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

TYPE & ENTER: